Abstract
Parkinsons disease (PD) is generally a sporadic disease, and only a small proportion of cases have a clear genetic component. During the last few years, a possible specific cause triggering death of dopaminergic neurons in the substantia nigra, drug of abuseinduced neurotoxicity, is being considered as a potential mechanism to develop PD, especially in the case of abuse of amphetamine and its derivatives. Recent evidences have shown pleiotrophin, a growth factor with important functions in remodeling and repair of injured neural tissue, as an important factor involved in the pathogenesis of both diseases by preventing neurodegeneration in Parkinsons disease, neurotoxicity induced by drug abuse and by its ability to modulate drugs addictive effects. This review discusses targeting growth factors such as glial-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to treat Parkinson ’ s disease and/or drug addiction and compiles recent evidences to propose the pleiotrophin/receptor protein tyrosine phosphatase β/ζ signaling pathway as a new therapeutic target to treat Parkinsons disease and to prevent drug of abuse-induced neurotoxicity and addictive effects.
Keywords: Pleiotrophin, midkine, drug abuse, neurodegeneration, GDNF, beta-catenin
Current Pharmaceutical Design
Title: Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Volume: 17 Issue: 5
Author(s): Esther Gramage and Gonzalo Herradon
Affiliation:
Keywords: Pleiotrophin, midkine, drug abuse, neurodegeneration, GDNF, beta-catenin
Abstract: Parkinsons disease (PD) is generally a sporadic disease, and only a small proportion of cases have a clear genetic component. During the last few years, a possible specific cause triggering death of dopaminergic neurons in the substantia nigra, drug of abuseinduced neurotoxicity, is being considered as a potential mechanism to develop PD, especially in the case of abuse of amphetamine and its derivatives. Recent evidences have shown pleiotrophin, a growth factor with important functions in remodeling and repair of injured neural tissue, as an important factor involved in the pathogenesis of both diseases by preventing neurodegeneration in Parkinsons disease, neurotoxicity induced by drug abuse and by its ability to modulate drugs addictive effects. This review discusses targeting growth factors such as glial-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to treat Parkinson ’ s disease and/or drug addiction and compiles recent evidences to propose the pleiotrophin/receptor protein tyrosine phosphatase β/ζ signaling pathway as a new therapeutic target to treat Parkinsons disease and to prevent drug of abuse-induced neurotoxicity and addictive effects.
Export Options
About this article
Cite this article as:
Gramage Esther and Herradon Gonzalo, Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164103
DOI https://dx.doi.org/10.2174/138161211795164103 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Cyclodextrins and their Derivatives as Carrier Molecules in Drug and Gene Delivery Systems
Current Organic Chemistry Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Evaluation of Cytotoxic Potentials of Some Isoindole-1, 3-Dione Derivatives on HeLa, C6 and A549 Cancer Cell Lines
Medicinal Chemistry Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Anticancer Active Heterocyclic Chalcones: Recent Developments
Anti-Cancer Agents in Medicinal Chemistry Rational Drug Design for Identifying Novel Multi-target Inhibitors for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Current Drug Targets Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery